Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Children 5 Through 11 Years of Age in European UnionGlobeNewsWire • 11/10/22
Pfizer Aims For A First In Respiratory Vaccines, But Is The Stock It A Buy Or A Sell?Investors Business Daily • 11/07/22
Pfizer-BioNTech bivalent booster shows higher immune response, but new COVID cases climb back above 40,000 a dayMarket Watch • 11/04/22
Pfizer Says Updated Booster Shot Sparks Stronger Immune Response Versus Original Vaccine—As Uptake Slows DrasticallyForbes • 11/04/22
Pfizer, BioNTech stocks rally after announcing positive trial data on BA.4/BA.5 bivalent booster shotMarket Watch • 11/04/22
Pfizer and BioNTech Announce Updated Clinical Data for Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Substantially Higher Immune Response in Adults Compared to the Original COVID-19 VaccineBusiness Wire • 11/04/22
GM, Audi, Pfizer Pull Ads From Twitter After Musk Sale—Here Are The Other Companies Rethinking Their TiesForbes • 11/04/22
Pfizer's Elranatamab Granted FDA Breakthrough Therapy Designation for Relapsed or Refractory Multiple MyelomaBusiness Wire • 11/03/22
Pfizer CEO reveals 2030 growth plan as company faces up to $18 billion revenue hit from genericsCNBC • 11/01/22